#France #gadopiclenol #Guerbet #Villepinte #Elucirem

Guerbet's Elucirem™: A Breakthrough in Pediatric Imaging

Introduction
The European Commission has granted approval for a new indication of Guerbet’s innovative gadolinium-based contrast agent, Elucirem™ (Gadopiclenol), specifically for use in children from birth. This approval revolutionizes pediatric magnetic resonance imaging (MRI) by allowing significantly lower doses, addressing concerns about gadolinium exposure in young patients.

What is Elucirem™?
Elucirem™ stands as a pioneering product from Guerbet, a global leader in medical imaging solutions. This macrocyclic gadolinium-based contrast agent boasts the highest relaxivity among currently available gadolinium-based contrast agents (GBCA). Initially approved in December 2023 for broader use, Elucirem™ is now officially indicated for both adults and children, including newborns, enhancing the detection of various pathologies affecting the brain, spinal cord, and other crucial organs.

The Importance of Lower Dosing
Traditional GBCA usage for MRIs often involves higher doses that raise concerns among healthcare providers about the cumulative exposure of patients to gadolinium. With Elucirem™, the required dosage for effective MRIs is reduced to half compared to other contrast agents, directly addressing these valid concerns. This is particularly paramount for pediatric patients who might require numerous imaging studies over their lifetime.

Valérie Brissart, Senior Vice President of Diagnostic Imaging at Guerbet, emphasized the impact of this new indication. “The introduction of Elucirem™ for pediatric patients reflects our commitment to merging medical innovation with patient safety. European radiologists can now perform contrast-enhanced MRIs with a significantly lower gadolinium dose, which is crucial for patients needing repeated assessments throughout their lives.”

Expert Insights on Pediatric Safety
Dr. Emilio J. Inarejos Clemente, Director and Pediatric Radiologist at Hospital Sant Joan de Déu in Barcelona, noted the importance of minimizing exposure to gadolinium in children. “Children are particularly vulnerable as they are still developing. The ability to achieve excellent image quality with only half the traditional gadolinium dose is a game-changer, ensuring both safety and diagnostic efficacy.”

Why is This a Game-Changer?
The implications of this advancement are profound:

• - Reduced Risk of Adverse Effects: Lower doses of gadolinium minimize the potential for side effects, especially in a population that is still growing and developing.
• - Greater Imaging Accessibility: More frequent imaging may now be viable for children without the same level of concern regarding gadolinium exposure, potentially improving outcomes through timely diagnosis.
• - Enhanced Diagnostic Confidence: Centers can leverage improved image quality provided by Elucirem™, encouraging the use of MRI examinations without hesitation regarding safety.

About Guerbet
With nearly a century of innovation, Guerbet has led the way in medical imaging, manufacturing a comprehensive portfolio of pharmaceuticals and medical devices. They invest heavily in research, contributing 9% of their revenue to R&D initiatives aimed at advancing imaging technology. Guerbet, listed on Euronext Paris, recorded a revenue of €841 million in 2024, showcasing their robust position in the industry.

Conclusion
Guerbet’s Elucirem™ represents a significant leap in the safety and efficacy of pediatric imaging. By introducing the capability to conduct high-quality MRIs with reduced gadolinium doses, the company highlights its commitment to innovation that prioritizes patient welfare, particularly in vulnerable populations such as newborns. With this breakthrough, the future of pediatric diagnostics appears brighter and more secure.

For more about Guerbet and Elucirem™, please visit Guerbet.